Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Ronghua, Tu"'
Autor:
Chengde Wu, Gong Zhen, Xijun Sheng, Chen Shuhui, Shoubo Zhang, Jie Shen, Huqiang Lv, Wang Xuehai, Jun Wang, Zhibo Qi, Hu Guoping, Sun Wenjie, Sun Guanglong, Yuchuan Zhu, Weifeng Mao, Liang Shen, Xuejun Zhang, Yan Pan, Minghui Cui, Ronghua Tu, Dongling Hao, Shuhua Han, Shen Chunli, Xin Li, Li Yi, Lei Huang, Jian Li
Publikováno v:
ACS Medicinal Chemistry Letters. 11:1863-1868
The identification and lead optimization of a series of pyrazolo[3,4-d]pyridazinone derivatives are described as a novel class of potent irreversible BTK inhibitors, resulting in the discovery of compound 8. Compound 8 exhibited high potency against
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c3f1f21257cb83e14e533ceaa55167e4
https://doi.org/10.1021/acsmedchemlett.9b00395
https://doi.org/10.1021/acsmedchemlett.9b00395
Autor:
Xuejun, Zhang, Xijun, Sheng, Jie, Shen, Shoubo, Zhang, Wenjie, Sun, Chunli, Shen, Yi, Li, Jun, Wang, Huqiang, Lv, Minghui, Cui, Yuchuan, Zhu, Lei, Huang, Dongling, Hao, Zhibo, Qi, Guanglong, Sun, Weifeng, Mao, Yan, Pan, Liang, Shen, Xin, Li, Guoping, Hu, Zhen, Gong, Shuhua, Han, Jian, Li, Shuhui, Chen, Ronghua, Tu, Xuehai, Wang, Chengde, Wu
Publikováno v:
ACS Med Chem Lett
[Image: see text] The identification and lead optimization of a series of pyrazolo[3,4-d]pyridazinone derivatives are described as a novel class of potent irreversible BTK inhibitors, resulting in the discovery of compound 8. Compound 8 exhibited hig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::09e6ebe288047e74c531f0c5efed0826
https://pubmed.ncbi.nlm.nih.gov/33062165
https://pubmed.ncbi.nlm.nih.gov/33062165
Autor:
Li Gang, Chen Shuhui, Ronghua Tu, Jie Shen, Guoqiang Ma, Sun Wenjie, Yue Yang, Chen Hailiang, Charles Z. Ding, Zhixiang Zhang
Publikováno v:
Cancer Research. 78:4845-4845
Objective: Poly-ADP-ribose polymerase (PARP) participates in DNA repair, replication and transcription, and is important to maintaining genome stability and integrity. PARP inhibitors have proven to be efficacious in the clinic to treat BRCA-deficien
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::311693b7e2225822a991512257c586fe
https://doi.org/10.1158/1538-7445.am2018-4845
https://doi.org/10.1158/1538-7445.am2018-4845
Autor:
Chengde Wu, Chunli Shen, Yuchuan Zhu, Guoping Hu, Jian Lin, Shuhui Chen, Qiang Xiao, Lu Huang, Hailiang Chen, Ronghua Tu, Yong Xu, Xuehai Wang
Publikováno v:
The Journal of Immunology. 196:210.16-210.16
Bruton’s tyrosine kinase (BTK) has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders, such as rheumatoid arthritis. Compounds were designed and evaluated in CADD based on published crystal s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97d728166b3d0bebaeb7b03d5c5eb7cb
https://doi.org/10.4049/jimmunol.196.supp.210.16
https://doi.org/10.4049/jimmunol.196.supp.210.16
Autor:
Yong Xu, Ronghua Tu, Hailiang Chen, Yang Yue, Lu Huang, Xuehai Wang, Chengde Wu, Chunli Shen, Liang Shen, Dongdong Wu, Jiahu Wu, Lexi Wang, Jian Li, Shuhui Chen
Publikováno v:
The Journal of Immunology. 196:210.17-210.17
BTK inhibition has been shown to be a potential approach to treat rheumatoid arthritis. We sought to develop an oral small molecule inhibitor in China market for rheumatoid arthritis. Our medchem group discovered a novel PCC WX486 which demonstrated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c351e6f0e5995a7a0a665be46c7b609
https://doi.org/10.4049/jimmunol.196.supp.210.17
https://doi.org/10.4049/jimmunol.196.supp.210.17
Autor:
Jian Lin, Chichung Chan, Chengde Wu, Chunli Shen, Shuhua Han, Xin Li, Tingting Guo, Shuhui Chen, Qiang Xiao, Lu Huang, Hailiang Chen, Ronghua Tu, Yong Xu, Xuehai Wang
Publikováno v:
The Journal of Immunology. 196:210.15-210.15
Bruton’s Tyrosine Kinase (BTK) plays a crucial role in B cell differentiation and proliferation, making it an attractive target to treat inflammatory and autoimmune diseases. A small molecule BTK inhibitor, WX486, showed a high potency and selectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::588d6e2a87343c437061fcb16824bc59
https://doi.org/10.4049/jimmunol.196.supp.210.15
https://doi.org/10.4049/jimmunol.196.supp.210.15